A Phase I Trial of the MUC1 Inhibitor, GO-203-2c, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase I Trial of the MUC1 Inhibitor, GO-203-2c, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs GO 203 2c (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 23 Nov 2016 Planned initiation date changed from 1 Dec 2016 to 1 Jun 2017.
    • 27 Jul 2016 Planned initiation date changed from 1 Feb 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top